Galapagos creates new warrant plan
May 17 2017 - 4:01PM
Mechelen, Belgium; 17 May 2017, 22.00 CET; regulated information
-- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that
its Board of Directors created 1,074,500 warrants under new
warrant plans for the benefit of employees, future employees,
directors and a consultant of the Company and its
subsidiaries.
On 17 May 2017, the Board of Directors of
Galapagos approved the "Warrant Plan 2017", a warrant plan intended
mainly for certain (future) employees of the Company and its
subsidiaries, and also for directors and an independent consultant
of the Company, and the "Warrant Plan 2017 RMV," a warrant plan
intended for certain employees of the Company's French subsidiary,
Galapagos SASU, within the framework of the authorized capital.
Under these warrant plans, 1,074,500 warrants were created, subject
to acceptances, and offered to the beneficiaries of the plans.
The offer of warrants to directors was approved
by the Annual Shareholders' Meeting held on 25 April 2017.
The warrants have an exercise term of eight
years as of the date of the offer and have an exercise price of
€80.57 (the average closing price of the share on Euronext
Amsterdam and Brussels during the thirty days preceding the date of
the offer). The warrants are not transferable and can in principle
not be exercised prior to 1 January 2021. Each warrant gives the
right to subscribe to one new Galapagos share. Should the warrants
be exercised, Galapagos will apply for the listing of the resulting
new shares on a regulated stock market. The warrants as such will
not be listed on any stock market.
Galapagos' total share capital currently amounts
to €274,854,440.18; the total number of securities conferring
voting rights is 50,815,648, which is also the total number of
voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued
securities conferring voting rights is 3,369,337, which equals the
total number of voting rights that may result from the exercise of
these warrants, and excludes the 1,074,500 warrants of Warrant
Plan 2017 and Warrant Plan 2017 RMV, which were created
subject to acceptance. Galapagos does not have any convertible
bonds or shares without voting rights outstanding.
About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 3, Phase 2,
Phase 1, pre-clinical, and discovery programs in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 530
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
CONTACT
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& CorporateCommunications+1 781 460 1784 |
Director
Communications+31 6 53 591 999communications@glpg.com |
Paul van
der HorstDirector IR & BusinessDevelopment+31 6 53 725 199 |
|
ir@glpg.com |
|
Forward-looking statementsThis release
may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but
not always, made through the use of words or phrases such as
"anticipates," "believes," "continues," "could," "estimates,"
"expects," "intends," "may," "plans," "seeks," "stands to," "we
believe," "will," "we intend," as well as similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from Galapagos' ongoing clinical research
programs may not support registration or further development of its
product candidates due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities
and Exchange Commission (SEC) filings and reports, including in
Galapagos' most recent annual report on form 20-F filed with the
SEC and subsequent filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0316826a-50f5-4df8-9ac5-391518eeefca
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Oct 2023 to Oct 2024